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Ovarian immature teratoma is a germ cell tumor that comprises less than 1% of ovarian cancers and is treated with surgical
debulking and chemotherapy depending on stage. Growing teratoma syndrome (GTS) is the phenomenon of the growth of mature
teratoma elements with normal tumor markers during or following chemotherapy for treatment of a malignant germ cell tumor.
These tumors are associated with significant morbidity and mortality due to invasive and compressive growth as well as potential
for malignant transformation. Current treatment modality is surgical resection. We discuss a 12-year-old female who presented
following resection of a pure ovarian immature teratoma (grade 3, FIGO stage IIIC). Following chemotherapy and resection of
a pelvic/liver recurrence demonstrating mature teratoma, she underwent molecular genetics based chemotherapeutic treatment.
No standardized management protocol has been established for the treatment of GTS. The effect of chemotherapeutic agents for
decreasing the volume of and prevention of expansion is unknown. We review in detail the history, diagnostic algorithm, and
previous reported pediatric cases as well as treatment options for pediatric patients with GTS.

1. Introduction
Growing teratoma syndrome (GTS) is thought to be the progression of immature to mature teratoma during or following
chemotherapy. GTS requires three criteria: normalization of
previously elevated tumor markers (AFP or 𝛽HCG), enlargement of the primary tumor, or finding of new tumor mass and
only mature teratoma elements on pathologic examination.
The incidence of GTS is 12% of ovarian germ cell tumors
(GCT) occurring in young adults and adolescents [1–3]. GTS
is most likely to occur if mature teratoma elements are found
in the primary tumor, and there is no reduction in tumor
size following chemotherapy or incomplete resection of the
primary tumor [4].

2. Case
A 12-year-old female patient presented from a referring institution in November 2015 for evaluation of 1-month history of

an enlarging abdominal mass. The patient reported a 4.5 kg
weight loss with increased lethargy. The physical examination
was normal except for a large abdominal solid mass. Pelvic
CT (Figure 1) revealed a large pelvic mass. Tumor markers
were significant for alpha fetoprotein (AFP) 656 ng/mL (nml
≤ 7 ng/mL), CA-125 401 U/mL (nml < 35 U/mL), and CEA
6.7 ng/mL (nml ≤ 3.5 ng/mL). Inhibin A/B and 𝛽-HCG levels
were normal. She underwent an exploratory laparotomy,
right salpingoophorectomy, omentectomy, peritoneal washings, diaphragmatic/peritoneal/pelvic biopsies, and periaortic lymph node biopsy. Intraoperative findings were significant for a distinct right ovarian mass with evidence of
prior rupture. Ascites was noted and aspirated. There was
peritoneal seeding along the pelvis and right pericolic gutter
and along the right hemidiaphragm. Gross residual disease
remained consisting mostly of the peritoneal seeding despite
removal of all gross abdominal disease. The cytology examination of the peritoneal fluid demonstrated no malignant
cells. Histologically, all the pathology specimens returned
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Figure 1: Initial imaging computed tomography of the abdomen and pelvis demonstrating a large pelvic tumor (arrow).

(a)

(b)

(c)

(d)

Figure 2: Initial ovarian teratoma with immature elements. (a) Sections of immature teratoma revealed a neoplasm composed of heterogenous
elements that included a dermoid cyst, fibroadipose tissue, cartilage, pigmented choroid, and glial tissue (H&E ×100). (b) Cystically dilated
glands with enteric differentiation were present (H&E ×100), (c) as well as several foci of immature neuroepithelium (H&E ×200). (d)
Immunohistochemical staining with glial fibrillary acid protein (GFAP) reveled teratoma deposits in the periaortic lymph node (GFAP ×200).

with high grade immature teratoma (Figure 2). She was
diagnosed as grade 3, FIGO stage IIIC. Chromosome analysis
returned trisomy 3 in four of her autosomal cells, consistent
with the diagnosis of immature teratoma. Since there is
currently no “standard of care” for pediatric grade immature
teratoma FIGO stage IIIC, we elected to follow tumor
markers closely. Following tumor markers, her AFP fell by

approximately 50% every week almost normalizing over the
course of three months from diagnosis (from 656 ng/mL
to 9.78 ng/mL). In January 2016, repeat tumor marker labs
demonstrated that AFP levels increased to 28.3 ng/mL and
CA-125/𝛽-HCG were within normal limits (18 units/mL CA125, <3 units/mL). Repeat CT of chest, abdomen, and pelvis
revealed that, in the abdomen and pelvis, she now had
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Figure 3: Computed tomography abdomen and pelvis follow-up imaging at 8 months. (a) Large mass occupying the right upper abdominal
cavity, revealing multiple new masses containing cystic and necrotic elements surrounding the liver (arrow). Because of tumor growth, the
giant mass had compressed the liver parenchyma. (b) Pelvic tumor is demonstrated as well (arrow).

enlarged peritoneal implants, as large as 3.5 × 1.5 cm, but no
other masses, and, in the chest, she had a 1.3 × 2 × 0.3 cm
left anterior pleural nodule, as well as bilateral diaphragmatic
lesions, 2.5 × 2.1 × 1.8 cm on right and 2.1 × 3 × 1.5 cm on left.
She subsequently underwent chemotherapy with bleomycin,
etoposide, and cisplatin (BEP) between February and May
2016 for high risk malignant ovarian germ cell tumor. After
4 cycles, her AFP was 0.84 ng/mL.
After 4 cycles, she underwent interval radiologic evaluation in preparation for second look surgery. The CT scan
of the chest, abdomen, and pelvis in May 2016 revealed a
significant increase in the size of the thoracic masses, as well
as the size and a number of abdominal and pelvic masses
(Figure 3). The largest mass was 7.9 × 7.7 × 8.7 cm in the
rectouterine pouch with evidence of fat and calcification.
There was also a 4.4 × 7.2 × 6.6 cm peritoneal implant
superior to the liver that also had similar visual findings.
There were also findings of bilateral cardiophrenic masses,
with the largest measuring 2.1 × 1.3 × 1.1 cm. In June 2016,
she underwent a second debulking procedure consisting of
complete infracolic omentectomy, para-aortic lymph node
dissection, hepatic mass resection, and pelvic tumor removal
on the right side. Gross residual disease remained in her
abdomen and pelvis, since she had innumerous peritoneal
studding, and thus her thoracic tumors were not removed. A
total of 5 pelvic masses and 3 liver masses were excised, and
pathologic analysis indicated mature teratoma (Figure 4). At
the time of surgery her liver masses were found to compress
the parenchyma of the liver and were not invasive.
Due to the massive growth of tumor in 4 months, as
well as recently undergoing 2 major surgical debulkings, and
still being unable to completely resect her tumors, medical
treatment was discussed with the patient and her parents. In
an attempt to prevent regrowth of her tumors, in August 2016,
the patient was started on experimental protocol #009 of the
Neuroblastoma and Medulloblastoma Translational Research

Consortium (NMTRC). This treatment regimen consists of
temozolomide 40 mg/m2 PO daily (days 1–28), tretinoin
25 mg/m2 /day PO BID (days 1–14), and sorafenib 150 mg/m2
PO BID (days 1–28). Thalidomide was started during cycle 2.
This protocol was chosen as this study tests the feasibility of
experimental technologies to determine a tumor’s molecular
makeup. This technology includes a genomic report based
on DNA exomes and RNA sequencing that will be used to
discover new ways to understand cancers and potentially
predict the best treatments for patients with cancer in the
future. Prior to the experimental therapeutics, a CT scan
was obtained to evaluate disease progression. She is currently
without new tumor growths.

3. Discussion
Immature ovarian teratoma is a rare germ cell neoplasm that
comprises <1% of ovarian teratomas [5]. The immature ovarian teratoma must be distinguished from the common benign
mature teratoma (dermoid cyst). The difference between the
malignant and benign tumors is the presence of immature
components most predominantly neuroectodermal, such as
neural and glial cells [6]. GCT typically present within the
first two decades of life. About 60–70% of malignant germ
cell ovarian tumors are diagnosed as FIGO stage I. Stage
IA dysgerminoma and grade-I immature teratoma without
ascites are treated effectively with surgery alone. In adults,
higher staging requires at least 3 courses of BEP (bleomycin,
etoposide, and cisplatin) chemotherapy, but children may not
need postoperative chemotherapy [7, 8]. The Children’s Cancer Group (CCG) recommends obtaining peritoneal fluid,
the removal of tumor without compromising surroundings
structures, sparing the fallopian tube if not adherent to the
tumor, examination of omentum with removal of suspicious
areas, and palpation of pelvic and para-aortic lymph nodes
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Figure 4: Histology of multiple pelvic lesions following repeat laparotomy demonstrated neoplasms composed of derivatives of all three germ
layers, namely, ectoderm, mesoderm, and endoderm consistent with mature teratoma. (a) Mature cartilage and squamous epithelium (H&E
×100). (b) Mature neuroglia and vascular proliferation (H&E ×200). (c) Cysts lined with mature squamous and ciliated columnar respiratory
epithelium and overlying mature neuroglia (H&E ×200). (d) Large cyst wall with gastric mucinous epithelium, bundles of smooth muscle,
and adjacent cysts lining of the ciliated respiratory epithelium (H&E ×200).

with biopsy in case of abnormality in malignant ovarian
tumors. Thus, the relative risk of incomplete staging is higher
for pediatric general surgeons [9]. Stratifying grade 3 tumors
by stage estimated 5-year event-free survival for patients
with grade 3, stage I/II disease was 0.92 (0.72–0.98) for
estimated proportion of event-free survival, whereas it was
0.52 (0.22–0.75) for grade 3, stage III patients (𝑝 = 0.005)
[10]. The overall survival for all grade 3 patients, regardless
of stage, was 100%. Neither the age at diagnosis nor the
AFP level was related significantly to the risk of relapse.
The administration of postoperative chemotherapy did not
decrease the risk of relapse in the pediatric cohort [10].
Similarly to our study, other pediatric studies have shown
no benefit of adjuvant chemotherapy postoperatively in the
management of ovarian immature teratomas. In a nonrandomized study by Göbel et al. [11], 76 patients were treated by
surgery alone, and 40 patients received adjuvant chemotherapy.
GTS was first introduced by DiSia et al. in 1977 and was
called “chemotherapeutic retroconversion” (CR) [12] while
Logothetis et al. in 1982 coined the term GTS [13]. Amsalem
et al. concluded that these two findings were likely the same
event [6]. Currently the pathologic mechanism is thought to
arise from either malignant cells differentiation into mature
elements or the fact that chemotherapy destroys immature
cells leaving mature cells to survive [14].

Ovarian GTS has been described in 101 published English
literature cases [15, 16]. Most of the patients had abdominal
symptoms, such as abdominal pain and distension when they
first sought evaluation. The median age for the diagnosis of
primary immature teratoma was 22 years (range 4–48 years,
𝑛 = 56) [15]. Many cases of GTS metastasis spread in the
peritoneal cavity and tend to occur in the pelvis, peritoneum,
or retroperitoneum but have been located in other places such
as the liver, pineal gland, and mediastinal/cervical lymph
nodes [7, 14, 17, 18]. A single case report described spread
via both the lymphogenous and hematogenous route in the
same patient [18]. GTS tumors have a growth rate of 0.5 to
0.7 cm/month and a volume increase of 9.2 to 12.9 cm3 /month
[19, 20].
Recurrent tumors following chemotherapy for germ cell
tumors should be resected to confirm diagnosis, relieve
impending/possible obstruction, and prevent future malignant transformation [6]. GTS has a high recurrence rate
between 72% and 83% with partial resection versus 0% and
12.7% in those who undergo complete resections [20, 21].
Laparoscopy can be utilized as a diagnostic and therapeutic
approach in cases of questionable or limited GTS [16].
GTS histology is comprised of mature teratoma elements,
but morbidity and mortality arise from its local expansion
and the potential for malignant degeneration [20, 22, 23].
There have been cases of safe IVC resection secondary to
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Immature teratoma

GCT with posttreatment mass
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No
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Consider recurrent or
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Figure notes:
(1) CT suggested in most
cases
(2) If lesion is inoperable
but compromising vital
structures, consider
reported experimental
treatments in lieu of
surveillance
(3) Consider risk of malignant
transformation/retransformation
as well as risk of continued
growth and mass effects
versus risk of surgery

No

Yes

No

Risks outweigh benefits?(3)

Yes

Figure 5: Algorithm suggested for management of pediatric female patients with ovarian germ cell tumors following initial resection of
immature teratoma and completion of therapy. GCT, germ cell tumor; GTS, growing teratoma syndrome. Modified from Byrd et al. with
permission.

production of collateral vasculature [24]. Approximately 3%
of GTS cases are associated with malignant transformation
including adenocarcinoma, sarcoma [25, 26], or primitive
neuroectodermal tumors [4]. GTS nodules can appear at
any stage during or after chemotherapy, up to 8 years

posttreatment, with an average interval of 8 months [22,
27, 28]. Therefore, regular follow-up contributes to early
detection, diagnoses, and treatment.
A rare form of tumor spread can be associated with GTS
known as Gliomatosis Peritonei (GP). This tissue is composed
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of mature glial tissue and can be located in the peritoneal
cavity and omentum in patients with ovarian teratoma. GP
is often mixed with GTS series despite this being a separate
entity [13] because it is defined by pure mature glial tumor
tissue in the peritoneum [29–31] and is encountered in a
variety of clinical scenarios [29, 32, 33]. For example, GP
can be found in children with ventriculoperitoneal shunts
where it is thought that the cerebrospinal fluid’s neural growth
factor induces glial differentiation [34, 35]. GP ultimately acts
as a prognostic factor for patients with immature ovarian
teratoma as those with GP have a shorter recurrence-free
survival (2-year recurrence-free survival rates were 59.3 if
with GP versus 96.3% without) [36]. In pediatric patients,
larger studies are needed to confirm this and it has not been
thought to be true, and the presence of GP does not upstage
them.
No standardized management protocol has been established, but one has been set out by Byrd et al. [1, 37] (Figure 5).
A key point regarding patients with GTS is regular followup as the majority of GTS is found on routine followup and presents without symptoms [21, 37]. MR imaging
and CT are the preferred modalities [38]. CT scan may
show a low-density cystic lesion or an increase in the cystic
component of the mass suggestive of teratomatous element
[39]. CT imaging typically shows radiographic maturation
including increased density, better circumscribed margins
and onset of internal calcifications, an amalgamation of fat,
and solid/cystic components [21, 40]. A downside of CT
scans is that it underestimates tumor masses smaller than 12 cm particularity within the mesentery and omentum when
closely related to small bowel loops in the absence of ascites
[39]. FDG-PET as a modality for detection of multiple masses
associated with GTS has low utility for diagnosis as the GTS
lesions do not uniformly appear as hypermetabolic tissue
such as brain and thyroid [41]. Ultrasonographic surveillance
is made difficult by the variable appearance of these lesions
and it is also less sensitive for fat than other modalities [42];
but it contains no radiation for the patient.
Adjuvant chemotherapy with bleomycin, etopside, and
cisplatin is recommended for patients when diagnosed with
immature teratoma following primary surgery. Palbociclib,
a CDK4/6 inhibitor (PD0332991), is reported that it can
stabilize the vascularization of the tumor in pediatric patients
with an intracranial teratoma [43]. It is a selective reversible
inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Inhibition of CDK 4/6 blocks DNA synthesis by prohibiting
progression of the cell cycle from G1 to S phase [43]. The
main side effect appears to be reversible neutropenia [44].
It has been especially effective in pRB-expressing teratomas
(retinoblastoma protein) [45]. While further investigation of
the use of Palbociclib in patients with GTS should be carried
out [43], the number of major disease-related clinical events
decreases with use of Palbociclib as did the median number
of progression-free survival months for unresectable mature
teratoma [46]. Inoperable metastases have been known to
be treated with bevacizumab and cyclin-dependent kinase
inhibitors [47], with tumor marker AFP usually returned to
within the normal range [48, 49]. Interferon-alpha has been
successfully used in unresectable tumors to stop their growth
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for a prolonged period of time based on its antiproliferative
and antiangiogenetic abilities and by its immune modulatory
effect [50–53], but tumors while stabilized can stay the same
size [54, 55].
Surgical approaches stress fertility sparing surgery as
recommended for women of childbearing age. Successful
pregnancy following development of GTS has been reported
indicating necessity of fertility sparing approaches [56]. The
treatment of choice during childbearing age for immature
teratoma is composed of unilateral oophorectomy and in
the case of metastatic disease postoperative chemotherapy.
Preservation of fertility is a major concern for young patients
undergoing surgical bulking and chemotherapy. Low antimullerian hormone (AMH) levels are associated with a higher
incidence of posttreatment amenorrhea [57]. Options for
fertility preservation include embryo cryotherapy, oocyte
cryopreservation, ovarian autotransplantation, in vitro maturation (IVM), and oophoropexy [58]. New innovations in
cryotherapy, such as vitrification, allow for rapid cooling of
tissue and decrease the risk of intracellular crystallization and
damage.

4. Conclusion
In the setting of immature ovarian teratoma treated with
chemotherapy, a rapid growth rate in the presence of normalized serum tumor markers should raise suspicion of
GTS [20]. No effective medical treatment of GTS exists due
to its unresponsiveness to chemotherapy or radiotherapy.
Treatment is currently excision of GTS lesions and close
monitoring with imaging and tumor markers. Some trials
indicate various treatments such as CDK inhibitors for
inoperable disease or stabilizing growth of recurrent lesions.
GTS has an overall good prognosis with few reported deaths.
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